Log In
Print
BCIQ
Print
Print this Print this
 

Vpriv, velaglucerase alfa (GA-GCB)

  Manage Alerts
Collapse Summary General Information
Company Shire plc
DescriptionGlucocerebrosidase enzyme replacement therapy
Molecular Target Not applicable
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentMarketed
Standard IndicationGaucher's disease
Indication DetailsTreat Gaucher's disease; Treat Type I Gaucher's disease
Regulatory Designation

U.S. - Priority Review (Treat Type I Gaucher's disease);
EU - Orphan Drug (Treat Type I Gaucher's disease);
Japan - Standard Review (Treat Gaucher's disease);
Switzerland - Orphan Drug (Treat Type I Gaucher's disease)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today